Jing Qian
Wei Cheng
Shuangyan Li3
Di Gao
Yunhui Zhang- 1Department of Respiratory Medicine, The First People’s Hospital of Yunnan Province, Kunming University of Science and Technology Affiliated Hospital, Kunming, China
- 2Chongqing Key Laboratory of New Drug Screening from Traditional Chinese Medicine, Integrative Science Center of Germplasm Creation in Western China (Chongqing) Science City and Southwest University, SWU-TAAHC Medicinal Plant Joint R&D Centre, College of Pharmaceutical Sciences, Southwest University, Chongqing, China
- 3Department of Oncology, 920th Hospital of the Joint Logistics Support Force of PLA, Kunming, China
- 4Department of Pathology, The First People’s Hospital of Yunnan Province, Kunming University of Science and Technology Affiliated Hospital, Kunming, China
- 5College of Foreign Languages, Qingdao City University, Qingdao, China
by Qian J, Cheng W, Li S, Deng L, Gao D, Zhang X and Zhang Y (2026). Front. Pharmacol. 16:1727729. doi: 10.3389/fphar.2025.1727729
There was a mistake in Figures 2, 3, 6 as published. In Figures 2F,G, 3D, 6A,D, the compound name “Rhoifolin” was incorrectly spelled as “Phoifolin” in the bar graph for cell lines H358 and H1299. In Figure 2B, the legend label for the “48 h” time point was incorrectly written as “48 4”. In Figure 3D, the asterisks indicating statistical significance on the bar graph were omitted. The corrected Figures 2, 3, 6 appear below.
Figure 2. Effect of Rhoifolin on lung cancer cell migration and invasion. (A–D) Scratch assay showing the effect of Rhoifolin on the migration of H358 and H1299 cells. (E–G) Transwell invasion assays showing the effect of Rhoifolin on the invasion ability of H358 and H1299 cells. (H–K) Western blot analysis of EMT-related markers E-cadherin and N-cadherin in H358 and H1299 cells treated with Rhoifolin. Statistical significance was determined using p-values, with *p < 0.05, **p < 0.01, and ***p < 0.001 indicating significant differences between groups. “ns” denotes no statistical significance.
Figure 3. Effect of Rhoifolin on lung cancer cell cycle and apoptosis. (A) Flow cytometry analysis showing the effect of Rhoifolin on the cell cycle distribution of H358 and H1299 cells. (B,C) Western blot analysis of cell cycle proteins (CDK1,Cyclin B1) in the Rhoifolin-treated H358 and H1299 cells. (D) Flow cytometry analysis of apoptosis in H358 and H1299 cells treated with Rhoifolin. (E,F) Western blot analysis of apoptotic regulatory proteins (Bax and Bcl-2) in Rhoifolin-treated H358 and H1299 cells. Statistical significance was determined using p-values, with *p < 0.05, **p < 0.01, and ***p < 0.001 indicating significant differences between groups. “ns” denotes no statistical significance.
Figure 6. Verification of Rhoifolin potential targeting EPHB2. (A) qRT-PCR analysis of EPHB2 mRNA expression in H358 cells treated with Rhoifolin. (B) Immunofluorescence observation of EPHB2 protein localization and expression. (C,D) Western blot analysis of EPHB2 protein expression in H358 cells treated with Rhoifolin. (E) Molecular docking simulation of Rhoifolin binding to EPHB2. (F) RMSD analysis of the protein-ligand complex during the simulation. (G) RMSF analysis of the protein-ligand complex during the simulation. (H) Radius of gyration (Rg) analysis of the protein-ligand complex. (I) SASA analysis of the protein-ligand complex. (J) Hydrogen bond analysis of the protein-ligand complex during the simulation. (K) Free energy landscape of the protein-ligand complex during the simulation. (L) Dynamic change in binding free energy of the Rhoifolin-EPHB2 complex during 100 ns simulation. (M) Total binding free energy of the Rhoifolin-EPHB2 complex. (N) Free energy decomposition analysis of key residues in the Rhoifolin-EPHB2 complex.
The original article has been updated.
Generative AI statement
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: EPHB2, lung cancer, molecular dynamics simulations, network pharmacology, Rhoifolin (ROF)
Citation: Qian J, Cheng W, Li S, Deng L, Gao D, Zhang X and Zhang Y (2026) Correction: Network pharmacology, bioinformatics and in vitro/in vivo validation elucidate the anti-lung cancer activities and potential targets of Rhoifolin. Front. Pharmacol. 17:1788169. doi: 10.3389/fphar.2026.1788169
Received: 15 January 2026; Accepted: 30 January 2026;
Published: 12 February 2026.
Edited and reviewed by:
Vanessa Souza-Mello, Rio de Janeiro State University, BrazilCopyright © 2026 Qian, Cheng, Li, Deng, Gao, Zhang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yunhui Zhang, eXVuaHVpemhhbmczMTg4QDEyNi5jb20=
†These authors have contributed equally to this work